Kronik böbrek yetmezliğinde serum ürik asit düzeyleri

Amaç: Kronik böbrek yetmezliğinde (KBY) serum ürik asit düzeyi artar. Biz çalışmamızda diyalize girmeyen evre 3-5 KBY hastaları ile hemodiyalize giren hastaların serum ürik asit düzeylerini inceledik. Ayrıca diyalize girmeyen evre 3-5 KBY hastalarında serum ürik asit düzeyi ile ilişki faktörleri araştırdık. Gereç ve Yöntem: Çalışmamız hemodiyalize giren 46, diyalize girmeyen evre 3-5 KBY olan 93, toplam 139 hasta ile yapıldı. Hastaların kan biyokimyasal değerlerine bakıldı. Vücut kitle indeksleri (VKİ) hesaplandı. Bulgular: Hemodiyalize giren hastaların ortalama serum ürik asit düzeyi 6,4 ±1,2 mg/dl, prediyaliz KBY olarak takip edilen hastaların ortalalama serum ürik asit düzeyi ise 7,3 ±1,9 mg/dl idi (p0.05). Serum ürik asit düzeyi yüksek olan hastalarımızın ortalama VKİ’leri ve bel çevreleri daha fazla idi (p

Serum uric acid levels in chronic kidney disease

Objective: Serum uric acid levels increase in chronic kidney disease (CKD). In our study, we examined the levels of serum uric acid levels in predialysis patients with stage 3-5 CKD and patients undergoing hemodialysis. We also searched the factors related to serum uric acid levels of predialysis patients with stage 3-5 CKD. Materials and Methods: 139 patients were included in the study; 46 patients undergoing hemodialysis and 93 patients with stage 3-5 CKD who were followed without dialysis. Serum routine biochemical parameters were studied. Body mass index (BMI) were calculated. Results: Mean serum uric acid levels were 6.4 ±1.2 mg/dl and 7.3±1.9 mg/dl in hemodialysis patients and predialysis CKD patients, respectively (p<0.05). There was no significant difference among stages of CKD in predialysis patients on account of mean serum uric acid levels (p>0.05). In patients with higher serum uric acid levels, mean BMI and waist circumference were higher (p<0.05). Conclusion: Serum uric acid levels of hemodialysis patients are lower than they are in patients followed predialysis. BMI and waist circumference are the factors associated with serum uric acid levels in stage 3-5 CKD patients followed without dialysis.

___

  • 1. Shankar A, Klein R, Klein BE, Nieto FJ. The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study. J Hum Hypertens 2006; 20: 937-945.
  • 2. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 55: 1293-1301.
  • 3. Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007; 50: 239-247.
  • 4. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-2410.
  • 5. Kuo CF, Luo SF, See LC, et al. Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol 2011; 40: 116-121.
  • 6. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44: 642-650.
  • 7. Iseki K, Oshiro S, Tozawa M, et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001; 24: 691-697.
  • 8. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: 1-266.
  • 9. Levey AS, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
  • 10. Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther 2008; 324: 1-7.
  • 11. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-1190.
  • 12. Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56: 22-26.
  • 13. Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol 2001; 28: 1640-1646.
  • 14. Shahbazian H, Zand Moghadam A, Ehsanpour A, Khazaali M. Changes in plasma concentrations of hypoxanthine and uric acid before and after hemodialysis. Iran J Kidney Dis 2009; 3: 151-155.
  • 15. Bober J, Kedzierska K, Safranow K, et al. Influence of glucose in dialyzing fluid on purine concentrations in hemodialyzed patients with chronic renal failure. Nephron Clin Pract 2003; 95: 31-36.
  • 16. Kanbay M, Yilmaz MI, Sonmez A, et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol 2011; 33: 298-304.
  • 17. Satirapoj B, Supasyndh O, Chaiprasert A, et al. Relationship between serum uric acid levels with chronic kidney disease in a Southeast Asian population. Nephrology (Carlton) 2010; 15: 253-258.
  • 18. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928-933.
  • 19. See LC, Kuo CF, Chuang FH, et al. Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. J Rheumatol 2009; 36: 1691-1698.
  • 20. Seki S, Tsutsui K, Fujii T, et al. Association of uric acid with risk factors for chronic kidney disease and metabolic syndrome in patients with essential hypertension. Clin Exp Hypertens 2010; 32: 270-277.
  • 21. Şengül E, Binnetoğlu E, Yılmaz A. Kronik Böbrek Hastalarında Ürik Asit ve D vitamini Düzeyleri Arasındaki İlişki. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 2011; 20:163-167.
  • 22. Kanbay M, Solak Y, Dogan E, Lanaspa MA, Covic A. Uric acid in hypertension and renal disease: the chicken or the egg? Blood Purif 2010; 30: 288-295.
Fırat Tıp Dergisi-Cover
  • ISSN: 1300-9818
  • Başlangıç: 2015
  • Yayıncı: Fırat Üniversitesi Tıp Fakültesi
Sayıdaki Diğer Makaleler

Notalgia parestetika: Olgu sunumu

Volkan SUBAŞI, Ülkü AŞKIN

Salter ve pemberton pelvik osteotomilerinde iliak ve femoral otogreft uygulamalarımızın karşılaştırılması

Murat Mustafa İNCESU, Mehmet BULUT, MURAT GÜRGER, Lokman KARAKURT

Bazal hücreli karsinomun sağ ventriküle metastazı

Zuhal TORLAK, MURAT UĞURLUCAN, Burçe GÖKTAŞ, Adem UÇAR, ÖMER ALİ SAYIN, Onur GÖKSEL, Emin TİRELİ, Enver DAYIOĞLU

Bilateral karotid cisim tümörü: Olgu sunumu

Selda Kargın KAYTEZ, İLHAN ÜNLÜ, Hakan GÖÇMEN, Erdal SAMİM, Hakkı UZUNKULAOĞLU, Ender ŞAHİN

Histerektomi materyallerinde histopatolojik tanıların insidansı

REMZİ ATILGAN, Abdullah BOZTOSUN, Mehmet Reşat ÖZERCAN

Tepecik Eğitim ve Araştırma Hastanesi infeksiyon hastalıkları ve klinik mikrobiyoloji laboratuvarında izole edilen bakterilerin tigesiklin ve diğer antibiyotiklere duyarlılığının incelenmesi

ŞÜKRAN KÖSE, Gülfem ECE, Melda TÜRKEN, Ayhan GÖZAYDIN, Bengü TATAR

Makrokraniya oluşturmuş dev araknoid kistin rastlantısal tanısı: Olgu sunumu

Hakan AK, Varol AYDIN, Halil SAMANCIOĞLU

Hsg öncesi kullanılan melatoninin radyasyona bağlı gelişecek endometriyal ablasyon ve uterin displazik hücre gelişimi üzerine etkisinin incelenmesi

EKREM SAPMAZ, Nusret AKPOLAT

The timing of ventriculo-peritoneal shunt application at the late stage myelomeningocele repair

BEKİR AKGÜN, Necati ÜÇLER, Fatih Serhat EROL, METİN KAPLAN, Tolga GEDİZ, İlhan YILMAZ

Polysplenia with dextrocardia and absence of the vena cavaınferior: A case report

Ertan SAL, Lokman ÜSTYOL, M. Selçuk BEKTAŞ, Hayrettin TEMEL, Avni KAYA, Abdurrahman ÜNER